bottom line underweight rate reflect
view see downsid pressur street sale earn
forecast ilmn report result mix implic
better better perform china report sale
growth y/i ahead assumpt declin
street consensu china hardest hit region
decreas y/i better expect
manag start see run volum increas china march
april custom return lab scale
oper sequenc instrument revenu
y/i due covid disrupt system shipment
sequenc consum servic revenu grew mid-teen rate
due covid-rel stock higher licens revenu
restrict custom activ impli wors accord
manag research volum volum run connect
system april declin compar clinic
market resili research nearli
driver seen slower pace sponsor close
oper temporarili due shelter-in-plac polici overal
expect challeng quarter larger covid impact
previous model
timelin covid tailwind remain uncertain manag
see technolog play bigger role covid-rel test
ultra-high throughput screen test surveil program
research project although see import technolog
area remain cautiou timelin materi
covid tailwind
model updat updat ep estim
 note herein rais
target price base
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
exclud amort acquir intang non-cash interest one-tim item
 iprd write-off comput non-gaap dilut sharecount
exclud amort acquir intang non-cash interest one-tim item
 iprd write-off comput non-gaap dilut sharecount
compani data secur llc estim reuter
period end expens net incom attribut non-control incom attribut ep dilut share share alreadi ex amort cash flowoper cash cash exclud amort acquir intang non-cash interest one-tim item iprd write-off comput non-gaap dilut sharecountsourc secur llc estim compani report inc
price target
price target reflect price-to-earnings ratio earn estim multipl
discount median peer group open-end growth stock healthcar believ
appropri given current growth challeng upsid risk underweight rate includ
limit follow factor first faster larger contribut popul sequenc
program model would provid potenti upsid compar estim well
market see faster adopt diagnost greater forecast rebound china
faster ramp consum growth gener could see investor appetit name
increas could see downsid risk continu pattern downward guidanc revis
investor becom disillus stori
underweight rate reflect view see downsid pressur street sale
earn forecast
san diego california-bas inc develop manufactur market
life scienc tool use genom compani technolog encompass two major type system
microarray next gener sequenc via novaseq hiseq nextseq miseq miniseq
platform half compani revenu come consum use variou
platform follow instrument system servic outsourc sequenc genotyp
servic well servic contract product custom includ genom research center
compani agrigenom compani consum genom compani
